Pancreatic Cancer Research

ResearcherUniversity of CambridgeNo recent work listed

Alimu Dayimu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9998-7463; OpenAlex author ID A5042410207. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper

Papers 2

  1. Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-023-02170-9↗
  2. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-020-0846-2↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Juan W. Valle · 2 shared papers, 2020–2023 · strength 0.24
  2. Bristi Basu · 2 shared papers, 2020–2023 · strength 0.24
  3. Duncan Ian Jodrell · 2 shared papers, 2020–2023 · strength 0.24
  4. Pippa G. Corrie · 2 shared papers, 2020–2023 · strength 0.24
  5. Alan Anthoney · 1 shared paper, 2020 · strength 0.07
  6. David J. Propper · 1 shared paper, 2020 · strength 0.07
  7. Daniel H. Palmer · 1 shared paper, 2020 · strength 0.07
  8. Aarthi Gopinathan · 1 shared paper, 2020 · strength 0.07
  9. Rebecca J. Brais · 1 shared paper, 2020 · strength 0.07
  10. Albrecht Neeße · 1 shared paper, 2020 · strength 0.07
  11. Harpreet Singh Wasan · 1 shared paper, 2020 · strength 0.07
  12. David Arthur Tuveson · 1 shared paper, 2020 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.